Zweiker David, Sieghartsleitner Raphael, Fiedler Lukas, Toth Gabor G, Luha Olev, Stix Guenter, Gabriel Harald, Vock Paul, Lileg Brigitte, Strouhal Andreas, Delle-Karth Geort, Pfeffer Michael, Aichinger Josef, Tkalec Wolfgang, Steinwender Clemens, Sihorsch Kurt, Binder Ronald K, Rammer Martin, Barbieri Fabian, Mueller Silvana, Verheyen Nicolas, Ablasser Klemens, Zirlik Andreas, Scherr Daniel
Department of Cardiology, Medical University of Graz, 8036 Graz, Austria.
Third Department for Cardiology and Intensive Care, Klinik Ottakring, 1160 Vienna, Austria.
J Clin Med. 2020 Oct 13;9(10):3274. doi: 10.3390/jcm9103274.
Complete real-world data on the indications and outcomes of left atrial appendage closure (LAAC) outside of clinical trials are rare. In this study, we stratified patients undergoing LAAC by indication groups.
This analysis of the national multicentre Austrian LAAC Registry comprised all patients that underwent LAAC up until 2018 at the currently active centres in Austria. The baseline characteristics, procedural details and outcomes between the following indication groups were compared: bleeding as an indication for LAAC ("bleeding" group) vs. thromboembolism despite oral anticoagulation (OAC; "thromboembolism" group) vs. an intolerance to OAC for reasons other than the above ("other" group).
The analysis included 186 patients, with 59.7% in the "bleeding" group, 8.1% in the "thromboembolism" group and 32.2% in the "other" group. The CHADS score was the highest in the "thromboembolism" group and the HAS-BLED score was the highest in the "bleeding" group. The procedural outcomes were similar between groups (implantation success, 97.3%), with major complications occurring in 7.0% of patients. One-year survival free from stroke, bleeding or LAAC-associated hospitalisation was 83.9%, 90.0% and 81.4% in the "bleeding", "thromboembolism" and "other" groups, respectively ( = 0.891).
In routine clinical practice, LAAC was used in a heterogeneous patient population with atrial fibrillation (AF) and contraindication, inefficacy or intolerance to OAC. The long-term outcome was favourable in all groups.
临床试验之外关于左心耳封堵术(LAAC)的适应证和结局的完整真实世界数据很少。在本研究中,我们按适应证组对接受LAAC的患者进行了分层。
这项对奥地利全国多中心LAAC注册研究的分析纳入了截至2018年在奥地利当前所有活跃中心接受LAAC的所有患者。比较了以下适应证组之间的基线特征、手术细节和结局:以出血作为LAAC的适应证(“出血”组)与尽管接受口服抗凝药(OAC)仍发生血栓栓塞(“血栓栓塞”组)与因上述以外的原因对OAC不耐受(“其他”组)。
该分析纳入了186例患者,“出血”组占59.7%,“血栓栓塞”组占8.1%,“其他”组占32.2%。CHADS评分在“血栓栓塞”组中最高,HAS - BLED评分在“出血”组中最高。各组之间的手术结局相似(植入成功率为97.3%),7.0%的患者发生了主要并发症。“出血”组、“血栓栓塞”组和“其他”组中无卒中、出血或LAAC相关住院的1年生存率分别为83.9%、90.0%和81.4%( = 0.891)。
在常规临床实践中,LAAC用于患有心房颤动(AF)且对OAC有禁忌证、无效或不耐受的异质性患者群体。所有组的长期结局均良好。